4-氨甲基四氢吡喃 | 130290-79-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡喃类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 中文名称: 4-氨甲基四氢吡喃
• 中文别名: 4-甲胺四氢吡喃；4-氨基甲基四氢吡喃；四氢吡喃-4-甲胺
• 英文名称: 4-tetrahydropyranmethylamine
• 英文别名: (tetrahydro-2H-pyran-4-yl)methanamine；4-aminomethyltetrahydropyran；tetrahydropyran-4-ylmethanamine；tetrahydropyran-4-ylmethylamine；1-(tetrahydro-2H-pyran-4-yl)methanamine；(tetrahydro-2H-pyran-4-yl)methylamine；1-(tetrahydropyran-4-yl)methylamine；4-(aminomethyl)tetrahydro-2H-pyran；1-(oxan-4-yl)methanamine；oxan-4-ylmethanamine；4-(aminomethyl)tetrahydro-4H-pyran
• CAS: 130290-79-8
• 化学式: C₆H₁₃NO
• mdl: MFCD02179435
• 分子量: 115.175
• InChiKey: IPBPLHNLRKRLPJ-UHFFFAOYSA-N

物化性质

• 沸点：
  75 °C
• 密度：
  1.02

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  C
• 安全说明：
  S26,S36/37/39,S45
• 危险类别码：
  R34
• 海关编码：
  2932999099
• 危险品运输编号：
  2735
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H227,H314
• 储存条件：
  室温、密封保存，并确保干燥。

SDS

Name:	4-Aminomethyltetrahydropyran Material Safety Data Sheet
Synonym:	14,15-Dihydro-14-Hydroxyburnamenine-14-Carboxylic Acid Methyl Ester; Anasclerol; Methyl Vincaminate
CAS:	130290-79-8

Section 1 - Chemical Product MSDS Name:4-Aminomethyltetrahydropyran Material Safety Data Sheet
Synonym:14,15-Dihydro-14-Hydroxyburnamenine-14-Carboxylic Acid Methyl Ester; Anasclerol; Methyl Vincaminate

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
130290-79-8	4-Aminomethyltetrahydropyran	>97%	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Chronic exposure may cause effects similar to those of acute exposure.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately. Do NOT allow victim to rub eyes or keep eyes closed.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
If swallowed, do NOT induce vomiting. Get medical aid immediately.
If victim is fully conscious, give a cupful of water. Never give anything by mouth to an unconscious person.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If breathing is difficult, give oxygen. Do NOT use mouth-to-mouth resuscitation. If breathing has ceased apply artificial respiration using oxygen and a suitable mechanical device such as a bag and a mask.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Keep container tightly closed. Do not ingest or inhale. Use only in a chemical fume hood. Discard contaminated shoes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 130290-79-8: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: colorless
Odor: Amine-like
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 75 - 76 deg C @18mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H13NO
Molecular Weight: 115.18

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Acid chlorides, reducing agents, strong oxidizing agents, strong acids.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 130290-79-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Aminomethyltetrahydropyran - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION
Ecotoxicity:
Fish: Pseudomonas putida:

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: AMINES, LIQUID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 2735
Packing Group: III
IMO
Shipping Name: AMINES, LIQUID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 2735
Packing Group: III
RID/ADR
Shipping Name: AMINES, LIQUID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 2735
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 130290-79-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 130290-79-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 130290-79-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

应用

4-氨甲基四氢吡喃是药物化学与有机合成中的重要中间体。常利用其胺的亲核性来构建酰胺键或将其分子骨架连接到生物活性分子结构中。

制备

将11.4克（88.3毫摩尔）四氢吡喃-4-甲酰胺溶解于441毫升四氢呋喃（THF）中，冷却至0°C。在十分钟内分六份缓慢加入265毫摩尔的氢化铝锂，并用氮气吹扫反应烧瓶以排除空气。当反应混合物不再起泡时，将其加热回流6小时，然后冷却至0°C，滴加乙酸乙酯直至停止冒泡，接着逐滴滴加甲醇直到起泡完全消失。

随后依次加入10毫升水、10毫升15%的氢氧化钠溶液和30毫升水。分离有机层，并用氯仿洗涤剩余的灰色固体。将合并后的有机部分用硫酸钠干燥，过滤去除硫酸钠固体后，减压浓缩有机滤液以得到目标产物4-氨甲基四氢吡喃。

反应信息

• 作为反应物：
  描述：

  4-氨甲基四氢吡喃 在 sodium carbonate 、 三乙胺 作用下， 以 二氯甲烷 、 异丙醇 为溶剂， 反应 4.0h， 生成 维特克拉
  参考文献：
  名称：

  [EN] SOLID STATE FORMS OF VENETOCLAX AND PROCESSES FOR PREPARATION OF VENETOCLAX
  [FR] FORMES SOLIDES DU VÉNÉTOCLAX ET PROCÉDÉS DE PRÉPARATION DU VÉNÉTOCLAX

  摘要：

  披索替尼的固态形式、其药物组合物和用途的披露。还披露了披索替尼的制备过程。

  公开号：

  WO2017156398A1
• 作为产物：
  描述：

  N-tetrahydropyran-4-ylmethyl-phthalimide 在 氢溴酸 作用下， 生成 4-氨甲基四氢吡喃
  参考文献：
  名称：

  Prelog et al., Justus Liebigs Annalen der Chemie, 1938, vol. 535, p. 37,45

  摘要：

  DOI：
• 作为试剂：
  描述：

  4-氨甲基四氢吡喃 、 2-(2,4-二氯苯基氨基)-4-三氟甲基-嘧啶-5-羧酸 在 4-氨甲基四氢吡喃 作用下， 生成 2-(2,4-二氯苯基氨基)-4-三氟甲基嘧啶-5-羧酸[(四氢吡喃-4-基)甲基]酰胺
  参考文献：
  名称：

  Pyrimidine derivatives and their use as CB2 modulators

  摘要：

  本发明涉及新型嘧啶衍生物、含有这些化合物的药物组合物以及它们在治疗疾病，特别是疼痛方面的应用，这些疾病直接或间接由大麻素受体活性的增加或减少引起。

  公开号：

  US07635701B2

文献信息

• Dihydroquinazolines enhance 20S proteasome activity and induce degradation of α-synuclein, an intrinsically disordered protein associated with neurodegeneration
  作者：Taylor J. Fiolek、Christina L. Magyar、Tyler J. Wall、Steven B. Davies、Molly V. Campbell、Christopher J. Savich、Jetze J. Tepe、R. Adam Mosey

  DOI：10.1016/j.bmcl.2021.127821

  日期：2021.3

  traditional small molecule drug design and are often referred to as “undruggable”. The 20S proteasome is the main protease that targets IDPs for degradation and therefore small molecule 20S proteasome enhancement presents a novel therapeutic strategy by which these undruggable IDPs could be targeted. The concept of 20S activation is still relatively new, with few potent activators having been identified

  许多内在无序蛋白质 (IDP) 的聚集体或寡聚形式，包括 α-突触核蛋白，是帕金森病和阿尔茨海默病等神经退行性疾病的标志，也是其发病机制的关键因素。由于其无序的性质，因此缺乏明确的药物结合口袋，IDPs 是传统小分子药物设计的困难目标，通常被称为“不可药物”。20S 蛋白酶体是靶向 IDP 进行降解的主要蛋白酶，因此小分子 20S 蛋白酶体增强提供了一种新的治疗策略，通过该策略可以靶向这些不可成药的 IDP。20S 激活的概念仍然相对较新，迄今为止已确定的有效激活剂很少。在此处，我们合成并评估了一个二氢喹唑啉类似物库，并发现了几种有前景的新型 20S 蛋白酶体激活剂。对热门歌曲的进一步测试表明，它们可以增强 20S 介导的 α-突触核蛋白降解，这是与帕金森病相关的 IDP。
• SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
  申请人：OOST Thorsten

  公开号：US20140057916A1

  公开（公告）日：2014-02-27

  This invention relates to substituted 4-pyridones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection, and oncological diseases.

  这项发明涉及式1的取代4-吡啶酮及其作为中性粒细胞弹性蛋白酶活性抑制剂的用途，包含这些化合物的药物组合物，以及将其用作治疗和/或预防肺部、胃肠道和泌尿系统疾病、皮肤和眼睛的炎症性疾病以及其他自身免疫和过敏性疾病、移植物排斥反应和肿瘤性疾病的药剂的方法。
• [EN] BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLE COMME INHIBITEURS DES BROMODOMAINES
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2016146738A1

  公开（公告）日：2016-09-22

  Compounds of formula (I) and salts thereof: wherein R1, R2, R3, R4 are defined herein. Compounds of formula (I) and salts thereof have been found to inhibit the binding of the BET family of bromodomain proteins to, for example, acetylated lysine residues and thus may have use in therapy, for example in the treatment of autoimmune and inflammatory diseases, such as rheumatoid arthritis; and cancers.

  式（I）的化合物及其盐：其中R1、R2、R3、R4在此处定义。已发现式（I）的化合物及其盐能够抑制BET家族的溴结构域蛋白与例如乙酰化赖氨酸残基的结合，因此可能在治疗中发挥作用，例如在治疗自身免疫和炎症性疾病（如类风湿性关节炎）和癌症方面。
• [EN] PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE PYRIMIDO[5,4-D]PYRIMIDINE SERVANT D'INHIBITEURS D'ENT POUR LE TRAITEMENT DE CANCERS, ET LEUR COMBINAISON AVEC DES ANTAGONISTES DU RÉCEPTEUR DE L'ADÉNOSINE
  申请人：ITEOS BELGIUM SA

  公开号：WO2021170797A1

  公开（公告）日：2021-09-02

  The present invention relates to pyrimido[5,4-d]pyrimidine derivatives of formula (I), including pharmaceutically acceptable salts and solvates thereof. Compounds of the invention are inhibitors of ENT family transporter, especially of ENT1, and are useful as therapeutic compounds for the treatment of cancers. The invention also relates to the combined use of the pyrimido[5,4-d]pyrimidine derivatives with an adenosine receptor antagonist, for the treatment of cancers.

  本发明涉及式(I)的嘧啶并[5,4-d]嘧啶衍生物，包括其药用可接受盐和溶剂化合物。本发明的化合物是ENT家族转运蛋白的抑制剂，特别是ENT1的抑制剂，并且可用作治疗癌症的治疗化合物。该发明还涉及将嘧啶并[5,4-d]嘧啶衍生物与腺苷受体拮抗剂联合使用，用于治疗癌症。
• [EN] PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE PROTÉINE TYROSINE PHOSPHATASE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：CALICO LIFE SCIENCES LLC

  公开号：WO2020186199A1

  公开（公告）日：2020-09-17

  Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN 1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.

  本文提供了用于抑制蛋白酪氨酸磷酸酶的化合物、组合物和方法，例如蛋白酪氨酸磷酸酶非受体型2（PTPN2）和/或蛋白酪氨酸磷酸酶非受体型1（PTPN1），以及用于治疗对PTPN1或PTPN2抑制剂治疗有良好反应的相关疾病、紊乱和状况的方法，例如癌症或代谢性疾病。